Davy Xuesong Ouyang, Gang Chen*, Zhun Wang, Lei Zheng, Zhensheng Wang, Lei Liu, Annie Xiaoyu An, Jean-Pierre Wery, Jay Liu*, Xin Dong*, and Henry Q. Li
*Nanjing Galaxy Biopharmaceutical Co. Ltd., Nanjing, China
CD137 belongs to the TNF receptor super family, and its activation is essential to the function of T cells and NK cells.
Multiple agonistic CD137 antibodies are currently being tested for advanced cancer, and are expected to become important new clinical immunotherapeutics.
Preclinical models are essential for the efficacy assessment of investigational CD137 antibodies before entering the clinic; however, currently available immunocompetent animal models cannot meet this need e.g. syngeneics due to species specificity issues.